Dry eye. Other disorders of lacrimal gland
Conditions
Interventions
Intervention 1: Intervention :Nasal drop(15ml) contain of Almond-Viola odorata oil, 3 times a day, every time 2 drop in each nostril for 4 weeks. Intervention 2: Control:Nasal drop(15ml) contain of pl
Treatment - Drugs
Placebo
Intervention :Nasal drop(15ml) contain of Almond-Viola odorata oil, 3 times a day, every time 2 drop in each nostril for 4 weeks.
Control:Nasal drop(15ml) contain of placebo, 3 times a day, every time 2 drop in each nostril for 4 weeks.
Sponsors
Vice chancellor for research of Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: complaint of foreign body or dry eye and at least in one eye; TUBT score for 3 times after sequential measurements become less than 10 seconds or Schirmer test without topical anesthesia at least in one eye during 5 minutes become less than 10 millimeters or coloring cornea with flourocin at least in one eye; age 18-60 years old; ability to use nasal drop; complete the informed consent form; ability to come for follow up. Exclusion criteria: the Schirmer test be less than 5 millimeters ; TUBT test be less than 5 seconds ;severe corneal coloring ;corneal ulcer at least in that eye ; filamentous keranopathy in that eye ;pregnancy or breast feeding ;any eye Surgery in the last 6 months ;any change in diet in the last month or during treatment ;the use of any topical eye drug during last 7 days in the affected eye ; patients who use topical eye drug due to another eye disease ;people who use contact lens ;use of corticosteroid in the last month ;use of anti-inflammatory drug for eye during last month ;use of corticosteroid or systemic anti-inflammatory drug Simultaneously with treatment ;use of any edible supplement
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Foreign body sensation, photophobia, blur vision, Burning. Timepoint: Baseline,4weeks after starting the medication. Method of measurement: Filling OSDI questionnaire.;Tear Break Up time. Timepoint: Baseline,4weeks after starting the medication. Method of measurement: The time that takes for the first dry spot to appear following blinking after fluorescin instillation.;Tear secretion. Timepoint: Baseline,4weeks after starting the medication. Method of measurement: measurement Schirmer test- Wetting of the filter paper after 5 minutes.;Tear osmolarity. Timepoint: Baseline,4 weeks after starting the medication. Method of measurement: Tear osmolarity maesurment via TearLab device-miliosmol /lit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Aniseh saffarShahroodi
Shiraz University of Medical Sciences
Outcome results
None listed